Pyxis Oncology, Inc.
PYXS
$2.62
$0.020.77%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.59% | 4.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.75% | 4.07% | |||
| Operating Income | 22.72% | -19.46% | |||
| Income Before Tax | 22.72% | -21.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.71% | -19.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.71% | -19.88% | |||
| EBIT | 22.72% | -19.46% | |||
| EBITDA | 33.91% | -20.07% | |||
| EPS Basic | 18.31% | -18.66% | |||
| Normalized Basic EPS | 23.29% | -20.50% | |||
| EPS Diluted | 18.31% | -18.66% | |||
| Normalized Diluted EPS | 23.29% | -20.50% | |||
| Average Basic Shares Outstanding | 0.76% | 1.03% | |||
| Average Diluted Shares Outstanding | 0.76% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||